Global Vaccine Administration Devices Market Industry Overview and Forecast to 2031 - Market Analysis and Market Share

The Global Vaccine Administration Devices Market size in 2023 is USD 3.9 billion. The market share is projected to grow at a CAGR of 7.90% and reach USD 6.9 billion by 2031.

Global Vaccine Administration Devices Market -Industry Overview

The global vaccine administration devices market is expanding rapidly, driven by the growing global emphasis on immunization as a crucial component of public health. According to WHO, global coverage for the first dose of the HPV vaccine in girls increased from 20% in 2022 to 27% in 2023. This growth is largely due to continuing vaccination initiatives for a variety of infectious diseases, including influenza, COVID-19, and other endemic illnesses. Technological improvements in vaccine delivery technologies, such as needle-free and self-administered devices, are increasing vaccination efficiency and comfort, hence contributing to market growth.

Data Bridge Market Research Market Report provides details of new recent developments, market share, market trends on the basis of its segmentations and regional analysis, the impact of market players, analyses of opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market, contact Data Bridge Market Research's team of expert analysts. Our team will help you make informed market decisions to achieve business growth.

Global Vaccine Administration Devices Market Size and Market Analysis

Enhanced public health campaigns are critical in increasing vaccination uptake and combatting vaccine hesitancy, and they play an important role in the expansion of the vaccine administration devices industry.  For instance, the "It's On Us" campaign, which was established during the COVID-19 pandemic, effectively addressed vaccine safety concerns and encouraged inoculation through social media, public service announcements, and community involvement. By effectively addressing vaccination reluctance and misinformation, such initiatives help to boost immunization coverage, thus generating demand for effective vaccine administration devices. As a result, Databridge Market Research dived into comprehensively analyzing the market and unveiled that the Global Vaccine Administration Devices Market is increasing at a CAGR of 7.90%. Our detailed analysis forecasts that the market is valued at USD 3.9 billion in 2023 and is expected to grow upto USD 6.9 billion by 2031. Our meticulously created report, developed through comprehensive research and analytics, is a distinguished paper that unveils eye-opening data about the market.

Global Vaccine Administration Devices Market Dynamics

Global Vaccine Administration Devices Market Growth Drivers

Increased Alliance and immunization programs

The market is driven by increasing immunization programs, rapid increase in immunization initiatives and campaigns, and rising disease rates around the world. For instance, the GAVI Alliance and the Bill & Melinda Gates Foundation are actively participating in immunological campaigns, which should considerably boost the market for vaccination administration devices.

Rise in chronic diseases

The rise in chronic diseases, such as diabetes and heart disease, has led to greater awareness of the importance of vaccination in at-risk populations. The World Health Organization (WHO) estimates that NCDs kill 41 million people each year, which is 74% of all deaths globally. The main types of NCDs are cardiovascular diseases, cancers, chronic respiratory diseases, and diabetes. Patients with chronic conditions often require vaccines that prevent complications from diseases, driving the need for reliable and easy-to-use vaccine administration devices.

Global Vaccine Administration Devices Market Growth Opportunities

Expansion in Emerging Markets

Expansion in emerging markets is significantly impacting the vaccine administration devices sector, driven by the growing healthcare infrastructure and vaccination programs. For instance, India administered over 2 billion doses of vaccines in mid-2022. As Developing regions enhance their healthcare systems and vaccination efforts, there is a rising demand for innovative administration devices to manage the increased vaccine distribution.

Innovation delivering progressive technologies

The vaccine administration devices market is undergoing considerable transformation due to technological breakthroughs such as needle-free injectors and auto-disable syringes. For instance, the Biojector 2000, a needle-free injector, has been successfully utilized in vaccination campaigns for diseases such as influenza and measles, providing a painless alternative that lowers the chance of needle-stick injuries. Such developments not only increase the safety and efficiency of vaccine delivery, but also address major public health concerns, making them critical for the Global Vaccine Administration Devices Market growth.

Global Vaccine Administration Devices Market Growth Challenges

Environmental concerns

The disposal of single-use vaccine administration devices, such as syringes and vials, adds to medical waste and poses environmental and public health risks. According to the World Health Organization (WHO), around 16 billion injections are provided globally each year. The need for sustainable solutions continues to rise, but providing eco-friendly alternatives without sacrificing safety or increasing costs is a challenge for manufacturers. Consequently hampering Global Vaccine Administration Devices Market Growth. 

Differing prices

The high expense of sophisticated vaccine delivery technologies, such as needle-free injectors and auto-disable syringes, poses a unique barrier to their general adoption, particularly in low- and middle-income countries. For instance, needle-free injectors such as PharmaJet's Tropis witness drastic price variation which makes them difficult to afford for large-scale vaccination campaigns in areas with limited healthcare resources.

Global Vaccine Administration Devices Market Growth Restraints

Regulatory hurdles

Regulatory challenges have a substantial impact on the worldwide vaccine administration devices market, as they provide barriers to the timely approval and launch of new technologies. For instance, Indian Central Drugs Standard Control Organization (CDSCO) demands extensive data and local testing before issuing approval, which adds time and cost for firms looking to access this large market.

Global Vaccine Administration Devices Market Scope and Trends

• Innovations Such as 3M’s Smart Syringe incorporate electronic components to track and record injection data, such as dose administration and timing. This technology aims to improve the accuracy of vaccine delivery and enhance patient safety.
• The ICMR and Panacea Biotec have launched India's first phase three clinical trial to produce a dengue vaccine. Panacea Biotec produced DengiAll, India's indigenous tetravalent dengue vaccine, and the first trial participant was vaccinated at the Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences in Rohtak.
• Iran received a substantial shipment of 564,000 doses of Pneumococcal Conjugate Vaccine (PCV), supported by UNICEF. This significant delivery is part of a broader initiative to enhance the country's immunization efforts and improve public health outcomes.
• Vietnam's routine immunization program received a significant boost with the arrival of 490,600 doses of the DTP-HepB-Hib vaccine, provided by Australia in partnership with UNICEF. This crucial shipment supports Vietnam's ongoing efforts to enhance its vaccination coverage and protect children against a range of preventable diseases.

Global Vaccine Administration Devices Market Regional Analysis – Market Trends

Key Insights

• North America's substantial investment in vaccine R&D and public health initiatives supports market expansion. The U.S. and Canada, is a leading market for vaccine administration devices, driven by high healthcare expenditure and advanced medical infrastructure.
• In Europe, the vaccine administration devices market is substantial, fueled by well-established healthcare systems and supportive regulatory frameworks. The EU and the UK are key players, with an emphasis on the adoption of smart and automated devices to enhance efficiency and safety.
• The Asia-Pacific region is experiencing rapid growth in the vaccine administration devices market, driven by expanding healthcare infrastructure and large-scale vaccination programs in countries like China, India, and Japan. The adoption of advanced devices, including auto-disable syringes and needle-free injectors, is increasing due to extensive public health initiatives.
• The Middle Eastern and African region is progressively adopting both traditional and innovative vaccine delivery systems to enhance healthcare delivery and expand immunization coverage.

Global Vaccine Administration Devices Market Leading Players

• B.D. (U.S.)
• INOVIO Pharmaceuticals (U.S.)
• Vaxxas (U.S.)
• Gerresheimer AG (Germany)
• Corium Inc. (U.S.)
• Enesi (U.S.)
• Micropoint Technologies (Singapore)
• SCHOTT AG (Germany)
• 3M (U.S.)
• Mystic Pharmaceuticals (U.S.)
• NanoPass Rev (U.S.)
• Terumo Europe NV (Belgium)
• D'Antonio Consultants International, Inc. (U.S.)
• West Pharmaceutical Services, Inc. (U.S.)
• Mylan N.V. (U.S.)
• Medical International Technologies Inc. (Canada)
• Antares Pharma (U.S.)

Global Vaccine Administration Devices Market Recent Developments

• In December 2023, The US FDA temporarily placed a Phase III study of Inovio's proposed DNA cancer vaccine VGX-3100 on hold due to concerns regarding its delivery mechanism. The Food and Drug Administration (FDA) requested evidence to substantiate the shelf life of the disposable pieces of the Cellectra 5pSp device used to administer VGX-3100.
• In November 2023, UNICEF and Gavi provide $3.2 million in IT and waste management equipment to the Ministry of Health to help boost Uzbekistan's immunization programs.
• In March 2022, under an emergency agreement with UNICEF, the Japanese government handed out cold chain equipment to boost Zambia's long-term health system capability, including the distribution of life-saving COVID-19 vaccines.
• In November 2023, Vaxxas Announces and Publicizes Successful Phase I Clinical Trial for Measles and Rubella Vaccine Delivered Using its Proprietary High-Density Microarray Skin Patch; Plans for Phase I/II Trial in The Gambia, Africa.

SKU-55561